ACE2 News and Research

RSS

Anti-SARS-CoV-2 antibodies found in wild mustelids in France

A new study focused on the identification of SARS-CoV-2 infection in wild mustelids in the French region of Brittany.

26 Jan 2022

Cannabidiol inhibits SARS-CoV-2 replication in human cells and mice

In research recently published in the journal of Science Advances, an interdisciplinary team of researchers from the University of Chicago assessed the potential role of cannabidiol (CBD), a natural product extracted from the cannabis plant, to prevent and inhibit severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections in human cells and mice.

26 Jan 2022

Spike-mediated CFTR inhibition accounts for airway inflammation in COVID-19

A new study looks at the molecular level inhibition of the protective CFTR gene by the SARS-CoV-2 spike protein.

25 Jan 2022

Development of synthetic molecules that can bridge T cells with SARS-CoV-2 infected cells

Scientists have recently used synthetic biology to design primary human CD8 T cells to express Spike protein-specific chimeric antigen receptors (ACE2 CAR or anti-Spike CAR).

25 Jan 2022

Broad and potent neutralizing activity of human IgG1 LALA antibody against SARS-CoV-2 variants

A new study has focused on the identification, in vitro binding, and potent neutralizing activity of STI-9167 (plutavimab) against live viruses and pseudotype viruses.

25 Jan 2022

Impact of clustered mutations in SARS-CoV-2 Omicron spike function

In a new study, researchers explored the characteristics of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant of concern (VOC) Omicron BA.1 sublineage clustered mutations.

24 Jan 2022

Characterization of unique pathogenesis of SARS-CoV-2 Delta variant in mouse model

Researchers have investigated the pathology and inflammatory response to the Delta variant in mice.

24 Jan 2022

Alpaca-derived antibody fragment disrupts interaction between SARS-CoV-2 spike protein and human ACE2

Researchers have been investigating the potential for using nanobodies – special immune particles from llamas and alpacas – against the disease.

24 Jan 2022

Researchers discover mechanism behind SARS-CoV-2 entry into the brain

In a new study, researchers conducted an analysis of databases that have information on the transcriptomic and proteomic expression of ACE2, TMPRSS2, NRP1, and furin in several human brain areas.

24 Jan 2022

Researchers are in the race to beat Omicron

David Veesler and his lab members aren't getting much sleep these days. In the final weeks of 2021, he and his team worked around the clock to post four coronavirus papers on the preprint server bioRxiv.

24 Jan 2022

Researchers find ELF5 gene a leading candidate behind severe COVID-19

Are there any risk factors that predispose patients to severe COVID-19 outcomes? A recent study published in the medRxiv* preprint server sheds light on this popular question. Using a combination of population genetics to single-cell RNA sequencing, European researchers identified the respiratory epithelial cell-specific ELF5 gene as a potential mediator for severe COVID-19 cases.

24 Jan 2022

Study shows how SARS-CoV-2 Omicron evades our immune response and remains infective

A recent study published in the journal Science brings a detailed chemical and molecular perspective on the improved evasion of antibodies against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the retention of strong interactions with the receptor as two principal factors underneath the notorious transmissibility of the SARS-CoV-2 Omicron variant.

23 Jan 2022

Nirmatrelvir, Molnupiravir, and Remdesivir hold-up against SARS-CoV-2 Omicron variant in vitro

In a recent study posted to the bioRxiv* preprint server, researchers test three severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antivirals authorized for emergency use by the United States Food and Drug Administration (FDA) for their in vitro potency against several SARS-CoV-2 variants, including the currently dominant Omicron train.

23 Jan 2022

Novel SARS-CoV-2 mutations reported in chronic HIV patients

A new study describes the emergence of new SARS-CoV-2 variants in three immunocompromised patients.

23 Jan 2022

Robust BNT162b2 vaccine-induced B and T-cell immunity against early SARS-CoV-2 variants

Researchers describe the state of adaptive immunity following vaccination with the Pfizer-BioNTech BNT162b2 COVID-19 vaccine.

23 Jan 2022

Study supports that Omicron variant has shifted to better usage of Cathepsin B/L entry pathway

A new study analyzed new data on the Omicron variant and indicated the altered cell entry pathways compared to other variants.

21 Jan 2022

Study suggests SARS-CoV-2 Omicron variant spike mediated immune escape and tropism shift

A new study showed that the SARS-CoV-2 Omicron spike binds to its receptor with enhanced affinity and yet evades vaccine-elicited neutralizing antibodies and that a booster mRNA vaccine broadened the neutralization of Omicron.

21 Jan 2022

Nano-bubbles containing ACE2 protein can block infection from broad strains of SARS-CoV-2

Scientists at Northwestern Medicine and The University of Texas MD Anderson Cancer Center have identified natural nano-bubbles containing the ACE2 protein (evACE2) in the blood of COVID-19 patients and discovered these nano-sized particles can block infection from broad strains of SARS-CoV-2 virus in preclinical studies.

21 Jan 2022

The tetrapeptide tuftsin effectively impairs the binding of SARS-CoV-2 S1 to ACE2

In their recent study posted to the preprint server bioRxiv*, the researchers from China have shown that tuftsin, a natural phagocytosis-stimulating peptide, can effectively impair the binding of SARS-CoV-2 spike S1 subunit to ACE2 receptor in a dose-dependent manner and therefore can be considered a potential drug against SARS-CoV-2 infection.

20 Jan 2022

Researchers explore furin inhibitors as a potential tool for treating COVID-19 infection

A new study suggests that coronaviruses such as SARS-CoV-2 depend on a furin cleavage site between the S1/S2 subunits to enhance viral infectivity.

20 Jan 2022

ACE2 News and Research

Anti-SARS-CoV-2 antibodies found in wild mustelids in France

Cannabidiol inhibits SARS-CoV-2 replication in human cells and mice

Spike-mediated CFTR inhibition accounts for airway inflammation in COVID-19

Development of synthetic molecules that can bridge T cells with SARS-CoV-2 infected cells

Broad and potent neutralizing activity of human IgG1 LALA antibody against SARS-CoV-2 variants

Impact of clustered mutations in SARS-CoV-2 Omicron spike function

Characterization of unique pathogenesis of SARS-CoV-2 Delta variant in mouse model

Alpaca-derived antibody fragment disrupts interaction between SARS-CoV-2 spike protein and human ACE2

Researchers discover mechanism behind SARS-CoV-2 entry into the brain

Researchers are in the race to beat Omicron

Researchers find ELF5 gene a leading candidate behind severe COVID-19

Study shows how SARS-CoV-2 Omicron evades our immune response and remains infective

Nirmatrelvir, Molnupiravir, and Remdesivir hold-up against SARS-CoV-2 Omicron variant in vitro

Novel SARS-CoV-2 mutations reported in chronic HIV patients

Robust BNT162b2 vaccine-induced B and T-cell immunity against early SARS-CoV-2 variants

Study supports that Omicron variant has shifted to better usage of Cathepsin B/L entry pathway

Study suggests SARS-CoV-2 Omicron variant spike mediated immune escape and tropism shift

Nano-bubbles containing ACE2 protein can block infection from broad strains of SARS-CoV-2

The tetrapeptide tuftsin effectively impairs the binding of SARS-CoV-2 S1 to ACE2

Researchers explore furin inhibitors as a potential tool for treating COVID-19 infection

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News